Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673654 · ClinicalTrials.gov registry record · Phase 1
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 476
- Enrollment target
NCT06673654 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 476 participants.
The verdict
NCT06673654, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 476 participants
- Enrollment target
Study Summary
To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
Interventions
- DRUG Placebo
- DRUG Ruxolitinib Topical Cream 1.5%
- DRUG OPZELURA (Ruxolitinib) Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06673654
The ClinicalTrials.gov registry entry for NCT06673654 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 476 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06673654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06673654 about?
NCT06673654 is a clinical study titled "A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.". To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
What is the current status of trial NCT06673654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 476 participants. The study started on 2023-08-11. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT06673654?
The interventions under investigation include: Placebo (DRUG), Ruxolitinib Topical Cream 1.5% (DRUG), OPZELURA (Ruxolitinib) Cream (DRUG).
Who is sponsoring clinical trial NCT06673654?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.